Lactiga is a venture-backed, NIH-funded biotherapeutics company developing patented biologics to treat and prevent mucosal infections with a focus on improving the quality of life in patients with Primary Immunodeficiency Diseases. They are unlocking the full therapeutic value of human milk antibodies to create the next-generation of anti-infectives that can battle even the world’s most dangerous pathogens including Covid. Lactiga has earned multiple awards, media attention (Globe & Mail, CTV, Toronto Star) and is participating in the On Deck Health (ODH2) cohort.
AngelMD Profile: https://www.angelmd.co/en/startups/lactiga
Sanjay Prasad, MD, FACS leads a multi-sided marketplace platform startup helping patients (self-insured employers) find surgeons with the best outcome history by procedure.
Project Cure CEO Douglas Jackson, PhD shares the mission of Project Cure in a wide ranging discussion that illustrates the incredible supply chain expertise...
Hall Venture Partners is the venture fund sponsored by and investing alongside the Hall Family. The Halls are a 3rd generation family office that...
